Teva May have a Problem Resulting from Opioid Epidemic: Barbuto & Johansson, P.A. Updates Investors of Class Action Lawsuit Against Teva Pharmaceutical

Barbuto & Johansson, P.A. (“BARJO”) and Of Counsel, Neil Rothstein, Esq. (with over 30 years of Securities Class Action Experience, including cases against ENRON and Halliburton) reminds investors that they have until August 20, 2019 to contact the Firm to learn more about the class action filed against Teva Pharmaceutical Industries Limited (NYSE: TEVA), and the appointment and qualifications of lead plaintiff.
Stock Symbols

Biotech Brief: Reports Forecast Continued Rise in Revenues for Diabetic Ulcer Treatment Market

According to a report from Grand View Research, the global diabetic foot ulcer treatment market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.2% during the forecast period. “Rising prevalence of diabetes, increasing healthcare expenses, and rapidly growing geriatric population worldwide are some of the major factors driving the diabetic ulcer treatment market. The occurrence and complications of diabetes are increasing worldwide. Global prevalence of diabetes is high and still on the rise. In 2017 $850 billion dollars was the estimated worldwide expenditure of diabetes, it has continued to grow since then. An article on Diabetic Foot: Facts and Figures added: “In the United States, a total of $176 billion is spent annually on direct costs for diabetes; As much as one third of that will be spent on lower extremity complications, such as diabetic foot ulcers. Diabetic foot ulcerations are one of the most common complications associated w/ diabetes with a global annual incidence of 6.3%. The lifetime incidence of foot ulcers in diabetic patients is 34%. More than 50% of diabetic ulcers become infected and 20% of those w/ moderate-severe infection result in amputation. Diabetes contributes to approximately 80% of the 120,000 non-traumatic amputations performed yearly in the United States. More than half of those with heel osteomyelitis (a bone infection) will undergo high level amputation.” Active biotech companies with recent developments include: Hoth Therapeutics, Inc. (NASDAQ: HOTH), Midatech Pharma PLC (NASDAQ: MTP), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Acasti Pharma Inc. (NASDAQ: ACST) (TSX-V: ACST), Outlook Therapeutics, Inc. (NASDAQ: OTLK).
Stock Symbols

ASNA, BUD & TEVA – Bronstein, Gewirtz & Grossman, LLC Class Action Reminder

Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Stock Symbols

Barbuto & Johansson, P.A. reminds TEVA, EQT, FRED and RBGLY Shareholders of Class Action Deadlines

Barbuto & Johansson, P.A. (“BARJO”) and Of Counsel, Neil Rothstein, Esq. (with over 30 years of Securities Class Action Experience, including cases against ENRON and Halliburton) reminds investors of upcoming deadlines to petition the court for lead plaintiff in securities class action lawsuits against Teva Pharmaceutical Industries Ltd. (NYSE:TEVA); EQT Corporation (NYSE:EQT); and Fred’s, Inc. (NasdaqGS:FRED); and Reckitt Benckiser Group, Plc (OTC:RBGLY). If you purchased one of these stocks during their respective Class Periods set forth below and suffered losses, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Stock Symbols

Myasthenia Gravis Treatment Market to see strong growth and various Market opportunities during forecasts period…

Myasthenia Gravis Treatment Market Research Report (2019-2026) The latest research report titled, ‘ Global Myasthenia Gravis Treatment Market ‘ has been added by StraitsResearch, which covers the industry overview, market definition, future economic prospects, competition by key players, company profiles, supply (production), and consumption analysis.This intelligence study also provides a comprehensive analysis of the Myasthenia (more…)

Teva Announces FDA Approval of AirDuo(R) Digihaler(TM) (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo(R) Digihaler(TM) (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma. AirDuo(R) Digihaler(TM) is indicated for the treatment of asthma in patients aged 12 years and older. AirDuo(R) Digihaler(TM) is not used to relieve sudden breathing problems and won’t replace a rescue inhaler.
Stock Symbols

ASNA, BUD & TEVA – Bronstein, Gewirtz & Grossman, LLC Class Action Announcement

Attorney Advertising–Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Stock Symbols

Teva to Present New Data on AJOVY(R) (fremanezumab-vfrm) Injection at the American Headache Society’s 61st Annual Scientific Meeting

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Company will present 31 scientific abstracts for AJOVY(R) (fremanezumab-vfrm) injection at the 61st Annual Scientific Meeting of the American Headache Society, taking place in Philadelphia from July 11-14, 2019. AJOVY is indicated for the preventive treatment of migraine in adults.
Stock Symbols